Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

<p><b>Background</b></p> AZD2816 is a variant-adapted COVID-19 vaccine that expresses the full-length SARS-CoV-2 beta variant spike protein but is otherwise similar to AZD1222 (ChAdOx1 nCoV-19). This study aimed to evaluate the safety and immunogenicity of AZD1222 or AZD2816...

Full description

Bibliographic Details
Main Authors: Costa Clemens, SA, Jepson, B, Bhorat, QE, Ahmad, A, Akhund, T, Aley, PK, Bansal, H, Bibi, S, Kelly, EJ, Khan, M, Lambe, T, Lombaard, JJ, Matthews, S, Pipolo Milan, E, Olsson, U, Ramasamy, MN, Moura de Oliveira Paiva, MS, Seegobin, S, Shoemaker, K, Szylak, A, Villafana, T, Pollard, AJ, Green, JA
Other Authors: AZD2816 Study Group
Format: Journal article
Language:English
Published: Elsevier 2024

Similar Items